{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:16:53Z","timestamp":1789834613508,"version":"4.0.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T00:00:00Z","timestamp":1498694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jacl.2017.06.012","type":"journal-article","created":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T12:00:48Z","timestamp":1498305648000},"page":"1243-1256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis"],"prefix":"10.1016","volume":"11","author":[{"given":"Robert","family":"Wolk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehrin J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Thiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Tatulych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2017.06.012_bib1","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2017.06.012_bib2","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.06.012_bib3","doi-asserted-by":"crossref","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major\u00a0adverse cardiovascular events: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2017.06.012_bib4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib5","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/bjd.12490","article-title":"Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta-analysis","volume":"169","author":"Miller","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib6","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/jid.2009.112","article-title":"The risk of stroke in patients with psoriasis","volume":"129","author":"Gelfand","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3389\/fphys.2015.00365","article-title":"Endothelial barrier and its abnormalities in cardiovascular disease","volume":"6","author":"Chistiakov","year":"2015","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacl.2017.06.012_bib8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s12967-015-0738-z","article-title":"Chronic, not acute, skin-specific inflammation promotes thrombosis in psoriasis murine models","volume":"13","author":"Golden","year":"2015","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jacl.2017.06.012_bib9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archdermatol.2011.119","article-title":"Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET\/CT): a pilot study","volume":"147","author":"Mehta","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib10","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/eurheartj\/ehq042","article-title":"Psoriasis, inflammation, and vascular risk: a problem more than skin deep?","volume":"31","author":"Ridker","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.06.012_bib11","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1194\/jlr.M027367","article-title":"Psoriasis alters HDL composition and cholesterol efflux capacity","volume":"53","author":"Holzer","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2017.06.012_bib12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2012.06.068","article-title":"Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis","volume":"224","author":"Mehta","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.06.012_bib13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/bjd.12101","article-title":"The association between psoriasis and dyslipidaemia: a systematic review","volume":"168","author":"Ma","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib14","first-page":"343","article-title":"Serum lipids and lipoproteins in patients with psoriasis","volume":"17","author":"Taheri Sarvtin","year":"2014","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.jacl.2017.06.012_bib15","series-title":"Endotext","article-title":"The effect of inflammation and infection on lipids and lipoproteins","author":"Feingold","year":"2015"},{"key":"10.1016\/j.jacl.2017.06.012_bib16","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jacl.2017.06.012_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm (Lond)"},{"key":"10.1016\/j.jacl.2017.06.012_bib18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"5","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jacl.2017.06.012_bib19","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and\u00a0retreatment in moderate-to-severe chronic plaque psoriasis: a\u00a0randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib20","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.06.012_bib21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacl.2017.06.012_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib25","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacl.2017.06.012_bib26","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cll.2006.07.006","article-title":"Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy","volume":"26","author":"Jeyarajah","year":"2006","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.jacl.2017.06.012_bib27","series-title":"Lipoprotein (a) [Package Insert]","year":"2016"},{"key":"10.1016\/j.jacl.2017.06.012_bib28","series-title":"APO C-III Auto-N \u201cDAIICHI\u201d [Package Insert]","year":"2014"},{"key":"10.1016\/j.jacl.2017.06.012_bib29","series-title":"Paraoxonase-1 Activity (PON-1)","year":"2016"},{"key":"10.1016\/j.jacl.2017.06.012_bib30","series-title":"Anasolv LCAT [Package Insert]","year":"2014"},{"key":"10.1016\/j.jacl.2017.06.012_bib31","series-title":"Human SAA ELISA Kit [Package Insert]","author":"Abazyme","year":"2004"},{"key":"10.1016\/j.jacl.2017.06.012_bib32","series-title":"PLAC(R) Test ELISA Kit: Enzyme Immunoassay for the Quantitative Determination of Lp-PLA2 in Human Plasma and Serum [Package Insert]","year":"2014"},{"key":"10.1016\/j.jacl.2017.06.012_bib33","series-title":"Mercodia oxidized LDL ELISA [Package Insert]","author":"Mercodia","year":"2012"},{"key":"10.1016\/j.jacl.2017.06.012_bib34","series-title":"Roar Ex\u00a0Vivo CETP Activity Assay [Package Insert]","year":"2017"},{"key":"10.1016\/j.jacl.2017.06.012_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0885-4505(92)90005-J","article-title":"A rapid and simple quantification of human apolipoprotein E-rich high-density lipoproteins in serum","volume":"47","author":"Chiba","year":"1992","journal-title":"Biochem Med Metab Biol"},{"key":"10.1016\/j.jacl.2017.06.012_bib36","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/ATVBAHA.110.207142","article-title":"Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib","volume":"30","author":"Yvan-Charvet","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2017.06.012_bib37","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/ATVBAHA.106.138347","article-title":"Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL","volume":"27","author":"Yvan-Charvet","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2017.06.012_bib38","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2016.06.012","article-title":"Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis","volume":"75","author":"Wu","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2125.1999.00991.x","article-title":"LDL particle size: an important drug target?","volume":"48","author":"Rajman","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2017.06.012_bib40","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fphar.2015.00218","article-title":"HDL particle number and size as predictors of cardiovascular disease","volume":"6","author":"Kontush","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacl.2017.06.012_bib41","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ahj.2014.08.007","article-title":"Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study","volume":"168","author":"Andersson","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2017.06.012_bib42","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/art.39039","article-title":"Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism","volume":"67","author":"Ronda","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib43","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2013.09.020","article-title":"From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies","volume":"70","author":"Hugh","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","article-title":"Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jacl.2017.06.012_bib45","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.38974","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib","volume":"67","author":"Charles-Schoeman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacl.2017.06.012_bib47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/0003319710373749","article-title":"Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?","volume":"62","author":"Toms","year":"2011","journal-title":"Angiology"},{"key":"10.1016\/j.jacl.2017.06.012_bib48","first-page":"757","article-title":"Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention","volume":"5","author":"Mill\u00e1n","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jacl.2017.06.012_bib49","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/rheumatology\/keu224","article-title":"Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment","volume":"53","author":"Choy","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jacl.2017.06.012_bib50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacl.2007.02.004","article-title":"Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence","volume":"1","author":"Brown","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.06.012_bib51","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/CIRCULATIONAHA.113.002671","article-title":"High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy","volume":"128","author":"Mora","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2017.06.012_bib52","doi-asserted-by":"crossref","first-page":"e000344","DOI":"10.1161\/JAHA.113.000344","volume":"2","author":"Voros","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2017.06.012_bib53","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/pr.58.3.1","article-title":"Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis","volume":"58","author":"Kontush","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jacl.2017.06.012_bib54","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1136\/hrt.69.1_Suppl.S12","article-title":"Role of oxidised low density lipoprotein in atherogenesis","volume":"69","author":"Witztum","year":"1993","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacl.2017.06.012_bib55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1155\/2013\/432136","article-title":"Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment","volume":"34","author":"Cai","year":"2013","journal-title":"Dis Markers"},{"key":"10.1016\/j.jacl.2017.06.012_bib56","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.06.012_bib57","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0021-9150(91)90073-C","article-title":"Reverse cholesterol transport: physiology and pharmacology","volume":"88","author":"Franceschini","year":"1991","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.06.012_bib58","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacl.2017.06.012_bib59","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI118345","article-title":"Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures","volume":"96","author":"Van Lenten","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2017.06.012_bib60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5551\/jat.32854","article-title":"Role of LCAT in atherosclerosis","volume":"23","author":"Ossoli","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2017.06.012_bib61","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1194\/jlr.R024513","article-title":"Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?","volume":"53","author":"Kunnen","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2017.06.012_bib62","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11883-012-0235-2","article-title":"High-density lipoprotein and atherosclerosis: the role of antioxidant activity","volume":"14","author":"Bandeali","year":"2012","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2017.06.012_bib63","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.299.11.1265","article-title":"Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk","volume":"299","author":"Bhattacharyya","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2017.06.012_bib64","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4103\/1947-2714.103310","article-title":"Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases","volume":"4","author":"Litvinov","year":"2012","journal-title":"N Am J Med Sci"},{"key":"10.1016\/j.jacl.2017.06.012_bib65","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2174\/157016111797484071","article-title":"Lipoprotein(a): current perspectives","volume":"9","author":"Gouni-Berthold","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jacl.2017.06.012_bib66","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-4632.2009.03994.x","article-title":"Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity","volume":"48","author":"Pietrzak","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib67","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1179\/135100009X12525712409490","article-title":"A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis","volume":"14","author":"Hua","year":"2009","journal-title":"Redox Rep"},{"key":"10.1016\/j.jacl.2017.06.012_bib68","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1536\/ihj.15-346","article-title":"Inflammatory biomarkers and atherosclerosis","volume":"57","author":"Soeki","year":"2016","journal-title":"Int Heart J"},{"key":"10.1016\/j.jacl.2017.06.012_bib69","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jacl.2017.06.012_bib70","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacl.2017.06.012_bib71","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jacl.2017.06.012_bib72","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J Drugs Dermatol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417303562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417303562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T12:00:12Z","timestamp":1535716812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287417303562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1933287417303562"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2017.06.012","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2017.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}